SCIENCE: An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels

Speech sensitive to treatment response

 

Click here for more details.

Related Post

  • Posted on 15 May, 2025
    MEDIA RELEASE MELBOURNE, VIC – A major collaborative paper published in Alzheimer’s & Dementia introduces a critical roadmap for the...
    • Posted on 11 December, 2024
      MEDIA RELEASE Melbourne - December 2024 – Redenlab, a leader in innovative healthcare solutions, has partnered with the Queensland Institute of Medical...
      • Posted on 31 March, 2024
        Speech and language impairments are core features of the neurodevelopmental genetic condition Kleefstra syndrome. The speech, language and cognitive profile...